Burden of Myasthenia Gravis in the Czech Republic: Analysis of
the Nationwide Patient Registry

J 2025

Burden of Myasthenia Gravis in the Czech Republic: Analysis of the Nationwide Patient Registry

VOHÁŇKA, Stanislav; Ales TICHOPAD; Magda HORÁKOVÁ; Jana JUNKEROVA; Michala JAKUBIKOVA et. al.

Basic information

Original name

Burden of Myasthenia Gravis in the Czech Republic: Analysis of the Nationwide Patient Registry

Authors

VOHÁŇKA, Stanislav (203 Czech Republic); Ales TICHOPAD (203 Czech Republic); Magda HORÁKOVÁ (203 Czech Republic); Jana JUNKEROVA (203 Czech Republic); Michala JAKUBIKOVA (203 Czech Republic); Jiri PITHA (203 Czech Republic); Michaela TYBLOVA (203 Czech Republic); Daniela VLAŽNÁ (703 Slovakia, belonging to the institution); Katarina BRECIKOVA (203 Czech Republic); Jacek CUDNY (616 Poland) and Petr HAJEK (203 Czech Republic)

Edition

NEUROLOGY AND THERAPY, LONDON, SPRINGER LONDON LTD, 2025, 2193-8253

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30210 Clinical neurology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Impact factor

Impact factor: 4.000 in 2023

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s40120-024-00682-x

UT WoS

001370393700001

EID Scopus

2-s2.0-85211331722

Keywords in English

Myasthenia gravis; Burden of disease; MGC score; FVC; Refractory patients; MGQoL15

Abstract

V originále

IntroductionThe main goal of this study was to describe the Czech population of patients with MG in terms of demographics, disease characteristics, management approaches, and treatment trends.MethodsWe selected all patients, both incident and prevalent, who were enrolled in the Czech MyReg registry between August 24, 2015 and November 19, 2021. For the descriptive analysis, all patients enrolled in the registry, regardless of their date of diagnosis or date of enrolment, were included. We analyzed the following disease-related endpoints: myasthenia gravis composite (MGC) score, forced vital capacity (FVC), and Myasthenia Gravis Foundation of America (MGFA) clinical classification.ResultsThe incidence showed a consistent increasing trend from 0.62 to 3.13. The mean MGC score was 5.0 (median 4.0, 95% CI 4.7, 5.3) representing mild form of MG. The difference in FVC from the predicted value in patients during and without myasthenic crisis was 58.93% (95% CI 37.27, 80.59) and 75.93% (95% CI 74.87, 77.00), respectively. We identified 70 patients (5.0%) with refractory MG, of whom 58.6% were female. The MGFA classifications in those with refractory vs. non-refractory disease was as follows: IIa 21.8% vs 23.2%, IIb 45.3% vs 33.6%, and IIIb 14.1% vs 4.6%, respectively.ConclusionOur analysis shows that the incidence of MG is increasing in the Czech Republic and that patients with refractory disease, of whom up to 58% are female, have a higher burden of disease than non-refractory patients.

Cite

VOHÁŇKA, Stanislav; Ales TICHOPAD; Magda HORÁKOVÁ; Jana JUNKEROVA; Michala JAKUBIKOVA; Jiri PITHA; Michaela TYBLOVA; Daniela VLAŽNÁ; Katarina BRECIKOVA; Jacek CUDNY and Petr HAJEK. Burden of Myasthenia Gravis in the Czech Republic: Analysis of the Nationwide Patient Registry. NEUROLOGY AND THERAPY. LONDON: SPRINGER LONDON LTD, 2025, vol. 14, No 1, p. 227-242. ISSN 2193-8253. Available from: https://dx.doi.org/10.1007/s40120-024-00682-x.

@article{2470285,
   author = {Voháňka, Stanislav and Tichopad, Ales and Horáková, Magda and Junkerova, Jana and Jakubikova, Michala and Pitha, Jiri and Tyblova, Michaela and Vlažná, Daniela and Brecikova, Katarina and Cudny, Jacek and Hajek, Petr},
   article_location = {LONDON},
   article_number = {1},
   doi = {http://dx.doi.org/10.1007/s40120-024-00682-x},
   keywords = {Myasthenia gravis; Burden of disease; MGC score; FVC; Refractory patients; MGQoL15},
   language = {eng},
   issn = {2193-8253},
   journal = {NEUROLOGY AND THERAPY},
   title = {Burden of Myasthenia Gravis in the Czech Republic: Analysis of the Nationwide Patient Registry},
   url = {https://www.frontiersin.org/journals/oral-health/articles/10.3389/froh.2024.1473049/full},
   volume = {14},
   year = {2025}
}

TY  - JOUR
ID  - 2470285
AU  - Voháňka, Stanislav - Tichopad, Ales - Horáková, Magda - Junkerova, Jana - Jakubikova, Michala - Pitha, Jiri - Tyblova, Michaela - Vlažná, Daniela - Brecikova, Katarina - Cudny, Jacek - Hajek, Petr
PY  - 2025
TI  - Burden of Myasthenia Gravis in the Czech Republic: Analysis of the Nationwide Patient Registry
JF  - NEUROLOGY AND THERAPY
VL  - 14
IS  - 1
SP  - 227-242
EP  - 227-242
PB  - SPRINGER LONDON LTD
SN  - 21938253
KW  - Myasthenia gravis
KW  - Burden of disease
KW  - MGC score
KW  - FVC
KW  - Refractory patients
KW  - MGQoL15
UR  - https://www.frontiersin.org/journals/oral-health/articles/10.3389/froh.2024.1473049/full
N2  - IntroductionThe main goal of this study was to describe the Czech population of patients with MG in terms of demographics, disease characteristics, management approaches, and treatment trends.MethodsWe selected all patients, both incident and prevalent, who were enrolled in the Czech MyReg registry between August 24, 2015 and November 19, 2021. For the descriptive analysis, all patients enrolled in the registry, regardless of their date of diagnosis or date of enrolment, were included. We analyzed the following disease-related endpoints: myasthenia gravis composite (MGC) score, forced vital capacity (FVC), and Myasthenia Gravis Foundation of America (MGFA) clinical classification.ResultsThe incidence showed a consistent increasing trend from 0.62 to 3.13. The mean MGC score was 5.0 (median 4.0, 95% CI 4.7, 5.3) representing mild form of MG. The difference in FVC from the predicted value in patients during and without myasthenic crisis was 58.93% (95% CI 37.27, 80.59) and 75.93% (95% CI 74.87, 77.00), respectively. We identified 70 patients (5.0%) with refractory MG, of whom 58.6% were female. The MGFA classifications in those with refractory vs. non-refractory disease was as follows: IIa 21.8% vs 23.2%, IIb 45.3% vs 33.6%, and IIIb 14.1% vs 4.6%, respectively.ConclusionOur analysis shows that the incidence of MG is increasing in the Czech Republic and that patients with refractory disease, of whom up to 58% are female, have a higher burden of disease than non-refractory patients.
ER  -

VOHÁŇKA, Stanislav; Ales TICHOPAD; Magda HORÁKOVÁ; Jana JUNKEROVA; Michala JAKUBIKOVA; Jiri PITHA; Michaela TYBLOVA; Daniela VLAŽNÁ; Katarina BRECIKOVA; Jacek CUDNY and Petr HAJEK. Burden of Myasthenia Gravis in the Czech Republic: Analysis of the Nationwide Patient Registry. \textit{NEUROLOGY AND THERAPY}. LONDON: SPRINGER LONDON LTD, 2025, vol.~14, No~1, p.~227-242. ISSN~2193-8253. Available from: https://dx.doi.org/10.1007/s40120-024-00682-x.

Přehled o publikaci